Altesa BioSciences Presents New Phase 2 Vapendavir Challenge Study Results at 2026 American Society for Microbiology (ASM) Microbe Conference

New clinical findings further reinforce therapeutic potential of vapendavir as targeted approach to preventing rhinovirus-driven COPD exacerbations WASHINGTON, June 5, 2026 /PRNewswire/ -- Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.